Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 248

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Meta-analysis: Duration of First-Line Proton-Pump Inhibitor–Based Triple Therapy for Helicobacter pylori Eradication

Fuccio, Lorenzo, Minardi, Maria Eugenia, Zagari, Rocco Maurizio, Grilli, Diego, Magrini, Nicola, Bazzoli, Franco · 2007 · Annals of Internal Medicine

Abstract

BACKGROUND: Proton-pump inhibitor (PPI)-based triple therapy is the recommended first-line treatment for Helicobacter pylori infection. A consensus on treatment duration is lacking. PURPOSE: To summarize the benefits and harms of different durations of PPI-based triple therapy. DATA SOURCES: PubMed, EMBASE, the Cochrane Library, and proceedings of major meetings through May 2007. STUDY SELECTION: English-language reports of randomized, controlled trials that compared duration (7, 10, or 14 days) of triple therapy and in which adequate testing confirmed the initial H. pylori infection and its eradication. DATA EXTRACTION: Two authors independently extracted data on study design, treatment, number of patients enrolled and number of patients with successful eradication, disease at enrollment, testing, adverse effects, year of publication, publication format, and country. DATA SYNTHESIS: Of 21 included studies, 11 compared 7-day therapy with 10-day therapy, and 13 compared 7-day therapy with 14-day therapy. Meta-analysis yielded relative risks (RRs) for eradication of 1.05 (95% CI, 1.01 to 1.10) for 7-day compared with 10-day amoxicillin-containing triple therapy (10 studies) and 1.07 (CI, 1.02 to 1.12) for 7-day compared with 14-day therapy (11 studies). Meta-analysis of the 3 studies that compared 7-day with 14-day metronidazole-containing therapy yielded an RR of 1.08 (CI, 0.96 to 1.22). The 7-day versus 10-day comparisons yielded RRs of 1.03 (CI, 0.97 to 1.10) for peptic ulcer disease and 1.10 (CI, 1.02 to 1.20) for nonulcer dyspepsia. For the 7-day versus 14-day comparisons, the RRs were 1.04 (CI, 0.99 to 1.09) and 1.03 (CI, 0.88 to 1.20), respectively. The RRs for frequency of adverse events were 0.98 (CI, 0.85 to 1.14) and 1.08 (CI, 0.84 to 1.40) for 7-day therapy compared with 10- and 14-day therapy, respectively. Diarrhea and taste disturbance were the most frequently reported adverse events (5%). LIMITATIONS: Subgroup analyses were limited by the few studies evaluating different drug regimens and disease at enrollment. Seventeen of the included studies had poor methodological quality or inadequate reporting. CONCLUSION: Available data suggest that extending triple therapy beyond 7 days is unlikely to be a clinically useful strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-147-8-200710160-00008

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 41

  1. 10.1056/NEJMra020542 · DOI · Paper page
  2. 10.1046/j.1365-2036.2000.00744.x · DOI · Paper page
  3. 10.1155/2003/714124 · DOI
  4. 10.1136/gut.2006.101634 · DOI · Paper page
  5. 10.1046/j.1365-2036.2002.01169.x · DOI · Paper page
  6. 10.1111/j.1365-2036.2004.02029.x · DOI
  7. 10.1016/j.dld.2003.12.015 · doi:10.1016/j.dld.2003.12.015
  8. 10.1111/j.1572-0241.2005.00178.x · doi:10.1111/j.1572-0241.2005.00178.x
  9. 10.1111/j.1572-0241.2005.50019.x · doi:10.1111/j.1572-0241.2005.50019.x
  10. 10.1155/2006/258768 · doi:10.1155/2006/258768
  11. 10.1111/j.1523-5378.2007.00468.x · DOI
  12. 10.1111/j.1523-5378.2006.00459.x · doi:10.1111/j.1523-5378.2006.00459.x
  13. 10.1136/gut.2006.102269 · doi:10.1136/gut.2006.102269
  14. 10.7326/0003-4819-134-5-200103060-00008 · DOI · Paper page
  15. 10.1046/j.1365-2036.2003.01746.x · DOI
  16. 10.1093/aje/kwh090 · DOI · Paper page
  17. Mantel N, 1959, J Natl Cancer Inst, 22, 719
  18. Grade AJ, 1996, Gastroenterology, 110, A121, 10.1053/gast.1996.v110.pm8536848 · DOI
  19. Monès J, 1997, Gastroenterology, 112, A224
  20. Katicic M, 1996, Gut, 39, A144
  21. Kiyota K, 1999, J Gastroenterol, 34, 76
  22. 10.4038/cmj.v49i4.1921 · DOI
  23. 10.1016/S0016-5085(98)81029-9 · doi:10.1016/s0016-5085(98)81029-9
  24. 10.3748/wjg.v10.i5.668 · DOI
  25. Lamouliatte H, 1998, Gut, 43, A80
  26. 10.1046/j.1523-5378.2000.00012.x · doi:10.1046/j.1523-5378.2000.00012.x
  27. 10.1046/j.1523-5378.2000.00006.x · DOI
  28. 10.1111/j.1440-1746.1998.01557.x · doi:10.1111/j.1440-1746.1998.01557.x
  29. Ching CK, 1998, Hong Kong Med J, 4, 7
  30. 10.1046/j.1365-2036.1996.111282000.x · doi:10.1046/j.1365-2036.1996.111282000.x
  31. 10.1046/j.1365-2036.2000.00800.x · doi:10.1046/j.1365-2036.2000.00800.x
  32. 10.1111/j.1572-0241.2001.03519.x · doi:10.1111/j.1572-0241.2001.03519.x
  33. 10.1111/j.1523-5378.1996.tb00012.x · doi:10.1111/j.1523-5378.1996.tb00012.x
  34. 10.1046/j.1365-2036.1998.00382.x · doi:10.1046/j.1365-2036.1998.00382.x
  35. 10.1016/S0016-5085(00)84092-5 · doi:10.1016/s0016-5085(00)84092-5
  36. Palmas F, 2002, Panminerva Med, 44, 145
  37. Gisbert JP, 2001, Hepatogastroenterology, 48, 1383
  38. 10.1080/003655201300191978 · doi:10.1080/003655201300191978
  39. 10.1136/bmj.38414.515938.8F · DOI · Paper page
  40. 10.1016/S0140-6736(96)90538-3 · DOI · Paper page
  41. 10.1016/S1286-4579(03)00112-6 · DOI · Paper page

Cited by

See all 248

Metadata

Authors
Fuccio, L., Minardi, M. E., Zagari, R. M., Grilli, D., Magrini, N., & Bazzoli, F.
Venue
Annals of Internal Medicine
Published
2007-10-16
Volume
147
Issue
8
Pages
553-562
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2060752995
Cited by
248
References
6
FWCI
20.18
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Meta-analysis: Duration of First-Line Proton-Pump Inhibitor–Based Triple Therapy for Helicobacter pylori Eradication. https://app.cochat.ai/papers/10.7326/0003-4819-147-8-200710160-00008
The paper
Fuccio, L., Minardi, M. E., Zagari, R. M., Grilli, D., Magrini, N., & Bazzoli, F. (2007). Meta-analysis: Duration of First-Line Proton-Pump Inhibitor–Based Triple Therapy for Helicobacter pylori Eradication. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-147-8-200710160-00008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.